TWI238064B - A pharmaceutical composition for prophylaxis and treatment of diabetes - Google Patents
A pharmaceutical composition for prophylaxis and treatment of diabetes Download PDFInfo
- Publication number
- TWI238064B TWI238064B TW090105054A TW90105054A TWI238064B TW I238064 B TWI238064 B TW I238064B TW 090105054 A TW090105054 A TW 090105054A TW 90105054 A TW90105054 A TW 90105054A TW I238064 B TWI238064 B TW I238064B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- methyl
- pharmaceutical composition
- insulin sensitivity
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Description
A7 B7 1238064 五、發明説明(3 ) 發明頜城 本發明為有關醫藥組成物,包括:胰島素敏感性促進 劑及作用機制與此促進劑不同之一種或一種Μ上其他抗糖 尿病藥之混合。 發明背暑 近年來,糖尿病之病理學已愈來愈明瞭,同時,專對 各別病理情況之藥劑,亦已開發。於是,具有新穎作用機 制之各種藥劑,一個接著一個出現。 胰島素敏感性促進劑,因具有使受損之胰島素受體功 能回復正常之作用,亦知作為胰島素抗性瓦解劑,而於近 年來受到注目。 關於此等胰島素敏感性促進劑,已開發一種極有用之 化合物,如皮利嗣(pioglitazone)[Fujita等著,糖尿病( Diabetes), 12., 804 〜810 頁,1983 年,JP-A S55U980 年 )-22636號(EP-A 8203號),JP-A S61U986年)-267580號( EP-A 193256號)]。皮利嗣修復受損之胰島素受體功能, Μ使细胞中之葡萄糖蓮載者(與糖代謝有關之主要酵素系 統,如葡萄糖激酶,及與脂質代謝有關之酵素糸統,如脂 蛋白脂肪酶)之不均勻分佈成正常。結果,胰島素抗性瓦 解而改良葡萄糖耐性,及降低血漿中中性脂質及游離脂肪 酸之濃度。由於皮利酮之此等作用較徐進,及長期施予之 副作用機率亦低,此化合物用於疑為高度胰島素一抗性之 肥胖病患。 此外,胰島素敏感性促進劑例如CS-045, I*唑啶二酮 (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製
本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 3 38259D1 A7 1238064 B7 五、發明説明(4 ) (請先閲讀背面之注意事項再填寫本頁) 衍生物及經取代之〇*唑啶二酮衍生物,經報導與胰島素聯 合使用[JP-A H4(1992 )-66579, JP-A H4( 1 992)-69383, JP-AH5(1993)-202042]。然而,具有本發明特定組合之 翳藥組成物,仍未為人所知。 糖尿病乃具有各種病理表徼之慢性疾病,且伴隨著脂 質代謝失調及循環条失調Μ及糖代謝失調。結果,由許多 病例知糖尿病易引起各種併發症。因此,需選擇適合於個 別病例所患病況之藥劑。然而,如此選擇在臨床上時有困 難,因為單獨使用個別藥劑,在有些病例上不能帶來足夠 的效果,且有各種問題,例如劑量增加或長期給藥引起之 副作用。 發明槪诚 鑑於上述技術,本發明人經深入研究Μ開發抗糖尿病 藥,使得即使長期給藥實質上亦不會引起不良反應,且對 多數糖尿病患有效。因此,本發明人發現用胰島素敏感性 促進劑,例如上述藥劑,及作用機制與此促進劑不同之其 他抗糖尿病藥混合,能達成上述目的,據此而完成本發明 經濟部智慧財產局員工消費合作社印製 〇 因此,本發明乃有關: Γ)翳藥組成物,包括:胰島素敏感性促進劑與醛糖遷原酶 抑制劑,鯊烯合成抑制劑,費布雷(f i b r a t e )化合物及L D L 代謝促進劑之群中之至少一員之混合; 2)如1)之翳藥組成物,其中胰島素敏感性促進劑為下式之 化合物或其藥理學上可接受之塩, 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 4 38259D1 1238064 Λ7 Β7 五、發明説明(5 )
(請先閱讀背面之注意事項再填寫本頁) 式中,R示任意經取代之烴基或雜環基;Y示-C0-, - CH(OH) -或- NR3 -之基(式中,R3示任意經取代之烷基); m為0或1; η為0, 1或2; X示CH或N; A示化學鍵或Ci-7二、 價脂族烴基;Q示氧原子或硫原子;R1示氫原子或燒基; E環可任意具有1至4個取代基,且此取代基可任意與R1 聯合形成環;L及Μ各示氫原子,或L及Μ可彼此任意聯合 形成化學鍵; 3) 如2)醫藥組成物,其中化學式(I)所示之化合物為皮利 萌; 4) 如1)之醫藥組成物,係用預防或治療糖尿病者; 發明夕詳沭 經濟部智慧財產局員工消費合作社印製 本說明書所用之”胰島素敏感性促進劑”,指能修復受 損之胰島素受體功能,Μ使胰島素抗性瓦解,而促進胰島 素敏感性之任一種及所有醫藥物質。此胰島素敏感性促進 劑之實例,可述及化學式(I)之化合物或其藥理學上可接 受之塩。 於化學式(I), R所示任意經取代之烴基中,烴基述及 脂族烴基,脂環族烴基,脂環族-脂族烴基,芳族脂族烴 基及芳族烴基。此等烴基中,碳原子數宜為1至14。 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 5 38259D1 1238064 at B7 五、發明説明(6 ) 脂 族 烴 基 9 宜 為 具 有 1至8 個碳 原 子 者 〇 此 脂 族 烴 基 9 述 及 C 1 -8 飽 和 脂 族 烴 基 (如, 烷基), 例 如 9 甲 基 9 乙 基 > 丙 基 > 異 丙 基 , 丁 基 異 丁 基 ,第 二 丁 基 > 第 三 丁 基 戊 基 異 戊 基 9 新 戊 基 鴦 第 三 戊 基, 己 基 異 己 基 $ 庚 基 及 辛 基 及 C2 -8 不 飽 和 脂 族 烴 基 (如, 烯基, 一 組 甘 —* $ 炔基, 二 炔 基 ), 例如, 乙烯基, 1 -丙烯基, 2 -丙烯基, 1 -丁烯 基 2- 丁 烯 基 3- 丁 烯 基 2- 甲基 -1 -丙烯基, 1 -戊烯基, 2- 戊 烯 基 y 3- 戊 烯 基 4- 戊 烯 基, 3- 甲 基 -2 -丁烯基, 1 - 己 烯 基 > 3- 己 烯 基 > 2 , 4- 己 二 烯基 9 5- 己 烯 基 卜庚 烯 基 1 - 辛 烯 基 乙 炔 基 1 -丙 炔 基, 2_ 丙 炔 基 9 1 - 丁 炔 基 > 2- 丁 炔 基 9 3 - 丁 炔 基 繋 1 - 戊 炔 基, 2- 戊 炔 基 $ 3- 戊 炔 基 > 4- 戊 炔 基 負 1 - 己 炔 基 3- 己 炔 基, 2, 4- 己 二 炔 基 $ 5- 己 炔 基 $ 1 - 庚 炔 基 及 1 - 辛 炔 基 〇 脂 環 族 烴 基 ♦ 宜 為 具 有 3至7個 碳 原 子 者 〇 此 脂 環 族 烴 基 , 述 及 C3 -7 飽 和 脂 環 族 烴 基 (如, 環烷基), 例 如 9 環 丙 基 $ 環 丁 基 > 環 戊 基 9 環 己 基 及環 庚 基 > 及 C 5 -7 不 飽 和 脂 環 族 烴 基 (如, 環烯基, 環二烯基) 例 如 9 1 - 環 戊 烯 基 2- 環 戊 烯 基 3- 環 戊 烯 基 $ 卜 環己 烯 基 2- 環 己 烯 基 > 3- 環 己 烯 基 9 1 - 環 庚 烯 基 9 2- 環 庚烯 基 9 3- 環 庚 烯 基 及 2 , 4- (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 環庚二烯基。 脂環族-腊族烴基,述及由上述脂環族烴基與脂族烴 基混合形成者(如,環烷基-烷基,環烯基-烷基)中,具有 4至9個碳原子者,例如,環丙基甲基,環丙基乙基,環丁 基甲基,環戊基甲基,2 -環戊烯基甲基,3 -環戊烯基甲基 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 6 3 8 2 5 9 D 1 A7 1238064 B7 五、發明説明(7 ) ,環己基甲基,2-環己烯基甲基,3-環己烯基甲基,環己 基乙基,環己基丙基,環庚基甲基及環庚基乙基。 (請先閲讀背面之注意事項再填寫本頁) 芳族脂族烴基,宜為具有7至13個碳原子者(如,芳烷 基)。此芳族脂族烴基,述及C7-9苯烷基,例如,苯甲基, 苯乙基,1-苯乙基,3-苯丙基,2-苯丙基及1-苯丙基,及 Cii-i3萘烷基,例如,〇(-萘甲基,α-萘乙基,/3-萘甲 基及萘乙基。 芳族烴基,述及具有6至14個碳原子者,例如,苯基, 萘基(ct -萘基,/3 -萘基)。 於化學式(I), R所示任意經取代之雜環基中,雜環基 逑及例如含有1至4個選自氧原子,硫原子及氮原子中之雜 原子作構環原子之5至7員雜環基,及縮合環基。此縮合環 逑及,例如,由該等5至7員雜環基與含有1或2個氮原子之 6員環,苯環或含有1個硫原子之5員環縮合者。 經濟部智慧財產局員工消費合作社印製 此等雜環基之實例,包含2 -Btt啶基,3 -啦啶基,4 -吡 啶基,2 -嘧啶基,4 -嘧啶基,5 -嘧啶基,6 -喃啶基,3 -嗒 畊基,4 -塔畊基,2 -吡阱基,2 -吡咯基,3 -吡咯基,2 -咪 唑基,4 -眯唑基,5 -咪唑基,3 -吡唑基,4 -吡唑基,異噬 唑基,異垮唑基,2 -噬唑基,4-噬唑基,5 -瞜唑基,2 -B琴 唑基,4 -唑基,5 -唑基,1,2,4 -嗜二唑-5 -基,1,2, 4-三唑-3-基,1,2,3-三唑-4-基,四唑-5-基,笨并眯唑-2 -基,吲睬-3 -基,1 Η -吲唑-3 -基,1 Η -吡咯并[2 , 3 - b ]吡 畊-2 -基,ΙΗ-啦咯并[2,3-b]吡啶-6 -基,1H -眯唑并[4,5- b]吡啶-2 -基,1H -咪唑并[4,5-c]吡啶-2 -基,1H -咪唑并[ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 7 38259D1 1238064 A7 ___B7___ 五、發明說明(8 ) 4,5-b]吡畊-2-基及笨并吡喃基。其中,K吡啶基,11等唑 基或I*唑基為宜。 於化學式(I), R所示之烴基及雜環基,可於任何取代 位置,任意具有1至5個(宜1至3個)取代基。此取代基之實 例,包含:脂族烴基,脂環族烴基,芳基,芳族雜環基, 非芳族雜環基,鹵原子,硝基,任意經取代之胺基,任意 經取代之醯基,任意經取代之羥基,任意經取代之蹄基, 任意經酯化之羧基,脒基,胺甲醯基,胺磺醯基,磺酸基 ,氰基,叠氮基及亞硝基。 脂族烴基之實例,包含:Ci-15直鐽或具支鐽之脂族 烴基,例如,烷基,烯基,及炔基。 烷基較宜之實例,包含:Ci-io烷基,例如,甲基, 乙基,丙基,異丙基,丁基,異丁基,第二丁基,第三丁 基,戊基,異戊基,新戊基,第三戊基,1-乙基丙基,己 基,異己基,1,1-二甲基丁基,2,2 -二甲基丁基,3 ,3 -二 甲基丁基,2-乙基丁基,己基,戊基,辛基,壬基及癸基 --r----------裝·、----^---訂--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 : 基 含婦 包丙 喃 > 1X 例 , 實基 之烯 宜丙 較異 基 , 烯基 丙 烯 基 烯 乙 如 例 基 烯 基 烯 丙 I 11 I 基 甲 丁 基 烯 基 烯 丁 基 烯 丁 基 烯 丁- 1- 基 乙 基 甲 基 烯 丁 基 烯 戊 基 烯 戊 基 烯 戊 基 烯 戊 基 烯 戊- 3- 基 甲 基 烯 己 基 烯 己 基 烯 己 含 包 ο 例 基實 烯 之 己 宜 5-較 及基 基快 烯 己 基 炔 乙 如 例 基 炔 38259D1 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 1238064 A7 ___B7___ 五、發明說明(9 ) 1-丙炔基,2-丙炔基,1-丁炔基,2-丁炔基,3-丁炔基, 1- 戊炔基,2 -戊炔基,3 -戊炔基,4 -戊快基,1-己炔基, 2- 己炔基,3-己炔基,4-己炔基及5-己炔基。 脂環族烴基,逑及C3-12飽和或不飽和脂環族烴基, 例如,環烷基,環烯基及環二烯基。 環烷基較宜之實例,包含:C3-l0環烷基,例如,環 丙基,環丁基,環戊基,環己基,環庚基,環辛基,二環 [2.2.1]庚基,二環[2·2·2]辛基,二環[3·2·1]辛基,二 環[3·2·2]壬基,二環[3·3,1]壬基,二環[4·2·1]壬基及 二環[4·3·1]癸基。 環烯基較宜之實例,包含:C3-l0環烯基,例如,2-環戊烯-1-基,3-環戊烯-1-基,2-環己烯-1-基及3-環己 烯-1 -基。 環二烯基較宜之實例,包含:〇4-1〇環二烯基,例如, 2,4-環戊二烯-1-基,2,4-環己二烯-1-基及2,5-環己二烯 -1 -基。 芳基較宜之實例,包含:C6-i4芳基,例如,苯基, 萘基(1-萘基,2 -萘基),憩基,菲基及苊烯萘基。 芳族雜環基較宜之實例,包含:芳放單環雜環基,例 如,呋喃基,α吩基,吡咯基,嘮唑基,異枵唑基,I*唑 基,異〇*唑基,眯唑基,吡唑基,1,2,3 -吗二唑基,1,2, 4 -二唑基,1,3,4 -11琴二唑基,呋咕基,1,2,3 -噬二唑基 ,1,2,4-«二唑基,1,3,4-噬二唑基,1,2,3-三唑基,1, 2,4 -三唑基,四唑基,吡啶基,嗒阱基,嘧啶基,吡畊基 ------------裝 ---.--—訂--------- (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 9 38259D1 1238064 A7 __B7 五、發明說明(10) 經濟部智慧財產局員工消費合作社印製 及 三 畊 基 1 及 芳 族 縮 合 雜 環 基, 例 如 9 苯 并 呋 喃 基 $ 異 苯 并 呋 喃 基 苯 并 [b] B*吩基, 吲睬基, 異吲睐基, 1 H- B引 唑 基 > 苯 并 咪 唑 基 $ 苯 并 D咢 唑 基, 1 , 2- 苯 并 異 0咢 唑 基 苯 并 睡 唑 基 $ 1 , 2- 笨 并 異 噻 唑 基 ,1H -苯并三 三唑基, Pf啉基, 異 Df 啉 基 $ 哮 啉 基 $ Df 唑 啉 基, of 喏 咐 基 呔 咐 基 睐 啶 基 $ 嘌 呤 基 $ 喋 啶 基 $ 咔 唑 基, α -咔啉基, β - 咔 咐 基 > 7 -咔咐基, 吖啶基, 啡呜畊基, 啡1«畊基, 啡畊基, 啡 D咢 m 基 , m 嗯 基 > 啡 啶 基 啡啉 基 9 吲 阱 基 f 吡 咯 并 [1 $ 2- b]嗒 m 基 9 吡 唑 并 [1 ,5 -a ]啦啶基, 咪唑并[1 , 2- a]吡 啶 基 負 眯 唑 并 [1 ,5 ~ a ]吡啶基, 眯唑并[1 , 2- b] 嗒 肼 基 9 咪 唑 并 [1 ,2 -a ]嘧啶基, 1 ,2 ,4 -三唑并[4 , 3- a]吡 啶 基 及 1 , 2, 4- 三 唑 并 [4 ,3 -b]嗒畊基C > 非 芳 族 雑 環 基 較 宜 之 實 例, 包 含 環 氧 乙 基 $ 吖 丁 啶 基 9 氧 雜 環 丁 烧 基 $ 硫 雜 環 丁烷 基 吡 咯 啶 基 9 四 氫 呋 喃 基 9 四 氫 m 吩 基 J -X* 氫 吡 啶 基, 四 氫 吡 喃 基 > 嗎 福 啉 基 9 硫 代 嗎 福 啉 基 $ 氫 吡 肼 基 ,N- 吡 咯 啶 基 9 N - 氫 吡 啶 基 > N - 嗎 福 啉 基 及 硫 代 N - 嗎 福 啉基 〇 鹵 原 子 之 實 例 9 包 含 ·· 氟, 氯 溴 及 TMt 峨 〇 任 意 經 取 代 之 胺 基 中 9 經取 代 之 胺 基 述 及 N - 單 取 代 之 胺 基 及 N , N - 二 取 代 之 胺 基 〇 經取 代 之 胺 基 之 實 例 > 包 含 : 胺 基 而 具 有 1或2個 選 白 C 1 -1 〇烧基, C 2 - 1 0 烯 基 9 C2 -1 〇炔 基 $ 芳 基 雜 環 基 及 Ci -1 0釀基中之取代基者(如 > 甲 胺 基 % 二 甲 胺 基 9 乙 胺 基 二 乙 胺基 9 二 丁 胺 基 > 二 烯 丙 胺 基 環 己 胺 基 > 苯 胺 基 9 N- 甲 基 -苯基- 胺 基 $ 乙 醯 胺 基 9 -----------裝--------—訂--------- (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1 〇 3 8 2 5 9 D 1 1238064 經濟部智慧財產局員工消費合作社印製 A7 B7___ 五、發明說明(11) 丙醯胺基,苯甲醯胺基及菸撿釀胺基)。 醯基,述及C 1 - 1 3釀基,例如,C 1 - 1 〇烷醯基,C 3 1 〇 烯醯基,C4-10環烷醯基,C4-10環烯醯基及C6-12芳族羰 基〇 CKO烷醸基較宜之實例,包含:甲醯基,乙醸基, 丙醯基,丁醯基,異丁釀基,戊醯基,異戊醯基,三甲基 乙醯基,己醣基,庚醯基及辛醯基。c3-l0烯醯基較宜之 實例,包含:丙烯醸基,甲基丙烯醃基,巴豆醯基及異E 豆酿基。C4-l0環烷醢基較宜之實例,包含:環丁羰基, 環戊羰基,環己羰基及環庚羰基。〇4-1〇環烯醯基較宜之 實例,包含:2 -己烯羰基。C6M2芳族羰基較宜之實例, 包含:苯甲醯基,萘甲醸基及菸驗醯基。 經取代之醢基中之取代基述及,例如,Ci-3烷基, Ci-3烷氧基,鹵原子(如,氯,氟,溴,等),硝基,羥基 及胺基。 任意經取代之羥基中,經取代之羥基述及,例如,烷 氧基,環烷氧基,烯氧基,環烯氧基,芳烷氧基,醯氧基 及芳氧基。 烷氧基較宜之實例,包含:Cl-lo烷氧基,例如,甲 氧基,乙氧基,丙氧基,異丙氧基,丁氧基,異丁氧基, 第二丁氧基,第三丁氧基,戊氧基,異戊氧基,新戊氧基 ,己氧基,庚氧基及壬氧基。環烷氧基較宜之實例,包含 :(:3-10環烷氧基,例如,環丁氧基,環戊氧基及環己氧 基。烯氧基較宜之實例,包含·· C2-10烯氧基,例如,烯 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 7] o q o c π π 1 —----------裝-----—丨訂--------- (請先閱讀背面之注意事項再填寫本頁) 1238064 A7 B7五、發明說明(12) 丙氧基,巴豆氧基,2-戊烯氧基及3-己烯氧基。環烯氧基 較宜之實例,包含:C3-10環烯氧基,例如,2-環戊烯氧 基及2 -環己烯氧基。芳烷氧基較宜之實例,包含:C7-l0 芳氧基,例如,笨基-Ci-4烷氧基(如,苯甲氧基及笨乙氧 基)。醢氧基較宜之實例,包含:C2-i3醯氧基,更宜為 基: 氧含 醯包 丙, , 例 基實 氧之 醯宜 乙較 , 基 如氧 基芳 * ) 醯基 燒氧 4 i I 醯 異 及 基 氧 醯 例 基 氧 芳 4 IX J 6 個 2 或 基實 代之 取基 氧 芳 之 有代 具取 意經 任 。 可丨 基 氧 芳 此 i 基 基,氧 氧 ί 笨 萘子氯 及原4-基鹵: 氧 ,含 苯如包 , 例 , 如 ,例 氯 氟 溴 基 硫 烷 及 述 基 癍 之 代 取 經 此 中 基 锍 之 代 取 經 意 任 於 芳 及 基 硫 醯 基 硫 烷 芳 基 硫 烯 環 基 硫 烯 基 硫 烷 環 基 硫 含 包 例 實 之 宜 較 基 硫 烷 甲 如 例 基 硫 烷 基 硫 丁 異 基 硫 丁 基 硫 丙 異 基 硫 丙 基 硫 乙 基 硫 基含 硫包 戊 , 新例 , 實 基之 硫宜 戊較 異基 , 硫 基烷 硫環 戊。 , 基 基硫 硫壬 丁及 三 基 第硫 , 房 基 , 硫基 丁硫 二 己 第 , (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 環 如 例 基 硫 烷 環 ο 1 3 含 包 例 實 之 宜 較 基 硫 烯 ο 基 硫烯 己 , 環如 及例 基 , 硫基 戊硫 環烯 ο 9 1A 基2 Ϊ C 硫 基 硫 豆 巴 基 硫 丙 基 硫 烯 環 ο 基 硫 烯 己- 3 及 基 硫 烯 戊 如 例 基 硫 烯 環 ο 1- 3 C 含 包 例 實 之 宜 較 硫 烯 戊 環 含 包 例 實 之 宜 較 基 硫1-烧-C 芳基 。 苯 基 , 硫如 烯例 己 , 環基 2-硫 及烷 基芳 乙 苯 及 基 硫 甲 苯 如 /|\ 基 硫 烷 為 宜 更 基 硫 醯 3 1- 2 C 含 包 例 實 之 宜 較 基 硫 酺 ο \—/ 基 硫 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 12 38259D1 A7 1238064 B7_ 五、發明說明(l3 ) C2-4烷醯硫基(如,乙醯硫基,丙醯硫基,丁醯硫基及異 丁醢硫基)。 (請先閱讀背面之注意事項再填寫本頁) 芳硫基較宜之實例,包含:芳硫基,例如,苯 硫基及萘硫基。此芳硫基可任意具有1或2個取代基,例如 ,鹵原子(如,氯,氟,溴)。經取代之芳硫基之實例,包 含:4-氯笨硫基。 任意經酯化之羧基,述及例如,烷氧羰基,芳烷氧鑛 基及芳氧羰基。 烷氧羰基較宜之實例,包含:C2-5烷氧羰基,例如, 甲氧羰基,乙氧羰基,丙氧羰基及丁氧羰基。芳烷氧羰基 較宜之實例,包含:C8-l0芳烷氧羰基,例如,苯甲基氧 羰基。芳氧羰基較宜之實例,包含:(:7-15芳氧羰基,例 如,苯氧羰基及對-甲苯基氧羰基。 R所示之烴基及雜環基上之取代基中,KCi-1〇烷基, 芳族雜環基及C6-14芳基為宜,而MCl-3烷基,呋喃基, α吩基,笨基及萘基為特宜。 經濟部智慧財產局員工消費合作社印製 於化學式(I), R所示之烴基及雜環基上之取代基,若 為腊環族烴基,芳基,芳族雜環基或非芳族雜環基,可分 別具有1或1個Μ上(宜1至3個)合宜之取代基。此等取代基 之實例,包含:C卜6烷基,C2-6烯基,C2-6炔基,C3-7環 烷基,C6-X4芳基,芳族雜環基(如,α吩基,呋喃基,ft 啶基,鸣唑基及α唑基),非芳族雜環基(如,四氫呋喃基 ,Ν -嗎福啉基,硫代Ν -嗎福啉基,Ν -六氫吡啶基,Ν -啦略 啶基及Ν -六氫吡畊基),C7-9芳烷基,胺基,H -單-Cl-4燒 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1238064 經濟部智慧財產局員工消費合作社印制衣 A7 B7___ 五、發明說明(14) 胺基,Ν,Ν -二- C1-4烧胺基,C2-8醯胺基(如,乙醯胺基, 丙醸胺基及苯甲醯胺基),脒基,C2-8醯基(如,C2-8烷醯 基),胺甲醯基,N-單-Ci-4烷胺甲醯基,Ν,Ν-二-Ci-4烷 胺甲醢基,胺磺醯基,N-單-Ci-4烷胺磺醯基,Ν,Ν-二-Ci-4烷胺磺醯基,羧基,C2-8烷氧羰基,羥基,Cl-4烷氧 基,C 2 - 5烯氧基,C 3 - 7環烷氧基,C 7 - 9芳烷氧基,C 6 - 1 4 芳氧基,擁基,Cl-4烷硫基,C7-9芳烷硫基,C6-14芳硫 基,磺酸基,氰基,叠氮基,硝基,亞硝基及鹵原子。 於化學式(I), R宜為任意經取代之雜環基。R更宜為 吡啶基,鸣唑基或1«唑基而任意經1至3個選自Ci-3烷基, 呋喃基,I®吩基,苯基及萘基中之取代基所取代。 於化學式(II)中之R’,定義如同R,但是當m及η為0; X示CH; Α示化學鍵;Q示硫原子;R1, L及Μ示氫原子;及 Ε環未具有取代基時,R’不為苯并吡喃基。 於化學式(I)及(II), Υ示-C0-, -CH(OH) -或-NR3-(式 中,R3示任意經取代之烷基),宜為-CH(OH) -或- NR3-。!?3 所示之任意經取代之烷基中,烷基逑及例如(:卜4烷基,例 如,甲基,乙基,丙基,異丙基,丁基,異丁基,第二丁 基及第三丁基。取代基之實例,包含鹵素(如,氟,氯, 溴及碘),Cl-4烷氧基(如,甲氧基,乙氧基,丙氧基,丁 氧基,異丁氧基,第二丁氧基及第三丁氧基),羥基,硝 基及Ci-4釀基(如,甲醢基,乙醢基及丙醯基)。 符號hi為0或1 ,宜為0。 符號η為0, 1或2,宜為0或1。 -------------------訂—-------- (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 14 38259D1 1238064 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(〗5 ) X示CH或N ,宜為CH。 於化學式(I)及(II), A示化學鍵或C!-7二價脂族烴基 。此脂族烴基可為直鏈或具支鏈,及飽和或不飽和者。脂 族烴基之特例,包含:飽和脂族烴基[如,-CH2-, -CH( CH3卜,_(CH2)2-, -CH(C2H5)-, -(CH2)3-, -(CH2)4_, - (CH2)5-, -(CH2)6 -及- (CH2)7_]及不飽和脂族烴基[如,_ CH=CH-, -C(CH3)=CH-, -CH=CH-CH2-, -C(C2H5)=CH-,-CH2-CH=CH-CH2、 -CH2-CH2-CH=CH-CH2_, -ch=ch_ch=ch-CH2-及-CH=CH-CH=CH-CH=CH-CH2-。 A宜為化學鍵或 Ci-4二 價脂族烴基,此脂族烴基宜為飽和基。A更宜為化學鍵或-(CH2)2- 〇 R1所示之烷基,實質上如同上述R3所示之烷基。Ri宜 為氫原子。 於化學式(I)及(I I),部分化學式: 摩 宜示化學式:
E環於任何可取代位置,具有1至4個取代基。此等取 代基之實例,包含:烷基,任意經取代之羥基,鹵原子, 任意經取代之醯基及任意經取代之胺基。此等取代基之定 義實質上如同R所示之烴基及雜環基之取代基。 E環,亦即部分化學式: 苴示化學式:
(請先閲讀背面之注意事項再填寫本頁)
、1T 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 15 38259D1 經濟部智慧財產局員工消費合作社印製 1238064 A7 __B7___ 五、發明說明(ie) 式中,R2示氫原子,烷基,任意經取代之羥基,鹵原子, 任意經取代之醯基,硝基或任意經取代之胺基。 R2所示之烷基,任意經取代之羥基,鹵原子,任意經 取代之醯基及任意經取代之胺基,逑及如R所示之烴基及 雜環基之取代基。R2宜為氫原子,任意經取代之羥基或鹵 原子,更宜為氫原子或任意經取代之羥基,特宜為氫原子 或C 1 -4烷氧基。 於化學式(I)及(II),L及Μ示氫原子,或可任意地彼 此聯合形成化學鍵。L及Μ宜為氫原子。 於式中L及Μ彼此聯合形成化學鍵之化合物中,唑啶二 酮環之第5位上之雙鐽,存有(Ε)及(Ζ)異構物。 而且,於式中,L及Μ各示氫原子之化合物中,於唑啶 二麵環之第5位上之不對稱碳,存有(R)及(S)光學異構物 。該等化合物包含彼等(R) -及(S) -光學異構物及消旋異構 物0 化學式(I)或(II)所示之化合物之較宜實例,包含: 式中R為吡啶基,鸣唑基或α唑基而任意具有1至3個選自 Ci-3烷基,呋喃基,α吩基,苯基及萘基中之取代基者; m為0; η為0或1; X為CH; Α為化學鐽或- (CH2)2-; R1為氫 原子;E環,亦即部分化學式:
及R2為氫原子或Ci-4烷氧基;及L及Μ均為氫原子。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 16 3 8 2 5 9 D 1 (請先閱讀背面之注意事項再填寫本頁) 裝--------訂--------- 1238064 A7 B7 五、發明説明(17 ) 化學式(I)所示之化合物之較宜實例,包含: (1) 化學式(III)所示之化合物,例如,5-[4-[2-(3 -乙基 -2 -吡啶基)乙氧基]苯甲基]-2,4-1*唑啶二嗣;5-[4-[ 2-(4 -乙基-2-吡啶基)乙氧基]笨甲基]-2,4-1*唑啶二 酮;5-[4-[2-(5-乙基-2-吡啶基)乙氧基]苯甲基]-2,4 -噬唑啶二嗣(俗名:皮利酮);及5-[4-[2-(6_乙基- 2-吡啶基)乙氧基]苯甲基]-2,4-1*唑啶二嗣; (2) (R)-( + )- 5- [3-[4-[2-(2-呋喃基)-5 -甲基- 4- Β琴唑甲氧 基]-3 -甲氧笨基]丙基]-2,4 -唑啶二酮;及 (3) 5-[[4-[(3,4-二氫-6-羥基-2,5,7,8-四甲基-2卜1-苯 并吡喃-2-基)甲氧基]苯基]甲基]-2,4-α唑啶二酮(俗 名:特洛利萌(troglitazone)/CS-045)。(化學式(I)所 示化合物特佳為皮利酮)。 化學式(II)所示之化合物,宜為化學式(III)所示之 化合物及(R)-( + )- 5- [3-[4-[2-(2-呋喃基)-5 -甲基-唑甲氧基]-3 -甲氧苯基]丙基]-2,4 -fli唑啶二更宜為 皮利嗣。 化學式(I)或(II)所示之化合物之藥理學上可接受之 塩之實例如,與無機鹼形成之塩,與有機鹼形成之塩,與 無機酸形成之塩,與有機酸形成之塩,及與鹼性或酸性胺 基酸形成之塩。 與無機鹼形成之塩,較宜之實例包含:與鹼金雇如鈉 ,鉀等形成之塩,與鹼土金屬如鈣,鎂等形成之塩,及與 鋁,銨等形成之塩。_ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 1 7 3 8 2 5 9 D 1 (請先閱讀背面之注意事項再填寫本頁) 礬_ 經濟部智慧財產局員工消費合作社印製 A7 1238064 — B7 五、發明説明(18 ) (請先閲讀背面之注意事項再填寫本頁) 與有機鹸形成之塩,較宜之實例包含:與三甲胺,三 乙胺,吡啶,甲基吡啶,乙醇胺,二乙醇胺,三乙酵胺, 二環己胺,Ν,Ν -二苯甲基伸乙二胺等形成之塩。 與無機酸形成之塩,較宜之實例包含:與塩酸,氫溴 酸,硝酸,硫酸,磷酸等形成之塩。 與有機酸形成之塩,較宜之實例包含:與甲酸,乙酸 ,Η氣乙酸,反丁烯二酸,草酸,酒石酸,順丁烯二酸, 檸樣酸,丁二酸,蘋果酸,甲磺酸,苯磺酸,對-甲苯磺 酸等形成之塩。 與鹼性胺基酸形成之塩,較宜之實例包含:與精胺酸 *離胺酸,鳥胺酸等形成之塩,及與酸性胺基酸形成之塩 ,較宜之實例包含:與天冬胺酸,麩胺酸等形成之塩。 化學式(III)所示之化合物之藥理學上可接受之塩, 宜為與無機酸形成之塩,更宜為與塩酸形成之塩。尤其, 皮利酮宜Μ與塩酸形成之塩之形式使用。 經濟部智慧財產局員工消費合作社印製 化學式(I)或(II)所示之化合物或其塩,可依例如, JPA S55 ( 1 9 80 )-22636 (ΕΡ-Α8203 ) , JFA S60 ( 1 985 )-20 8980 (EP-A 1 55845 ), JPA S6 1 ( 1 986 ) - 286376 ( EP-A 208420 ) , JPA S6 1 ( 1 986 ) -85372 (EP-A 1 77353 ), JPA S 6 1 ( 1 986 )- 26 7 580 (EP-A 1 93256 ), JPA H5 ( 1 99 3 ) - 8 605 7 ( tfO 92/ 1 850 1 ), JPA H7 ( 1 995 )-8226 9 (EP-A 605228 ) , JPA H 7 ( 1 995 )- 1 0 1 945 (EP-A 6 1 2 743 ), EP-A 64305 0, EP-A 7 1 06 59,等所述之方法,或其類似方法,製得之。 胰島素敏感性促進劑,除了上述化合物之外,包含: 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X297公釐) 18 38259D1 1238064 at B7 五、發明説明(1 9 ) 5-[[3,4-二氫-2-(苯甲基)-2^1-苯并吡喃-6-基]甲基]- 2.4- ®_喷二嗣[俗名:安利酮(englitazone)]或其納塩; 5-[[4-[3-(5_甲基-2-苯基-4-呜唑基)-1-氧丙基]苯基]甲 基]-2,4-®!睡 _ 二嗣[俗名··達利酮(darglitazone)/CP -86325)]或其納塩; 5- [2-(5 -甲基-2 -苯基- 4-01唑甲基)苯并呋喃-5-基甲基]- 2.4- 1^唑啶二酮(〇?-92768); 5-(2-萘磺醯基)-2,4-¾ 唑啶二酮(AY-31637); 4 - [(2-萘基)甲基]-3H - 1,2,3,5 -二唑-2-氧化物(AY-30711) ; 及 5-[[4-[2-(甲基-2 -吡啶胺基)乙氧基]苯基]甲基]-2,4-« 唑咐二酮(BRL- 49 6 5 3 )等。 依本發明,與上逑胰島素敏感性促進劑混合使用之藥 物之實例包含:醛醣遨原酶抑制劑,鯊烯合成抑制劑,費 布雷化合物及L D L代謝促進劑。 醛醣遨原酶抑制劑,乃於多元醇途徑中抑制第一階段 速率限制酵素,以防止或阻擋糖尿病併發症之藥物。於糖 尿病之高血糖狀況,多元醇途徑中葡萄糖利用率增加,過 多之山梨糖醇蓄積於细胞內,終成組織毒素,而引起併發 症,例如,糖尿病性神經病,視網膜病,及腎病。醛糖遷 原酶抑制劑之實例,包含:妥路達(tolurestat);義巴達 (6戸31以3131:);3,4-二氫-2,8-二異丙基-3-硫酮基-2卜1, 4-苯并垮阱-4 -乙酸;2,7 -二氟基-螺(9H -舞-9,4’-咪唑啶 )-2’,5’-二_ [俗名:伊米達(imirestat)]; (請先閱讀背面之注意事項再填寫本頁) • 1— 、 經濟部智慧財產局員工消費合作社印製 —m^lm —Ηϋ· JmmmmMm—. 一 ^ Jmi ttm BUI ml —^ϋ mu I —am m I tmmue ·ϋιϋ Jin ml mu ml Hi-—·— -ϋϋ Biliif 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 19 3 8 2 59 A7 B7 1238064 五、發明説明(20 ) 3-[ (4 -溴-2-氟苯基)甲基]-7 -氯-3,4-二氫-2,4-二氧代基 - l(2H)-〇f唑咐乙酸[俗名:季那達(zenarestat)]; (請先閱讀背面之注意事項再填寫本頁) 6 -氟-2,3 -二氫-2 ’,5’-二氧代基-螺[4H-1-苯并吡喃-4,4’ -咪唑啶]-2 -羰胺(SNK-860 ); 若波達(zopolrestat);蘇比拿(sorbinil)及 1 - [(3-溴-2-苯并呋喃基)磺醯基]-2,4-眯唑啶二酮(M-16209),等。 鯊烯合成抑制劑為具有經由抑制鯊烯合成而降低血膽 固酵量之作用之藥物。 鯊烯合成抑制劑之實例包含:(5)-«-[雙[2,2-二甲 基-1-氧代基丙氧基)甲氧基]膦基]-3 -苯氧苯丁磺酸,單 鉀塩(BMS-188494)。 費布雷化合物為藉由抑制肝中三酸甘油酯之合成與分 泌及活化脂蛋白脂肪酶,而具有降低血膽固醇量之作用的 藥物。 經濟部智慧財產局員工消費合作社印製 費布雷化合物,實例包含··朋費布雷(bezafibrate), 貝可布雷(beclobrate),畢尼費布雷(binifibrate),賽 普費布雷(ciplofibrate),克諾費布雷(clinofibrate), 被脂乙酯(clofibrate),怯脂酸(clofibric acid),艾費 布雷(etofibrate),芬費布雷(fenofibrate),金費伯H( gemfibrozil),尼可費布雷(nicofibrate),派利費布雷( pirifibrate),羅尼費布雷(ronifibrate),辛費布雷( simfibrate),席費布雷(theofibrate),等。 LDL代謝促進劑,乃具有由增加LDL (低密度脂蛋白)受 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 20 3 8 259 A7 1238064 B7 五、發明説明(21 ) 體之數目,Μ降低血膽固醇量之作用的藥物。 (請先閲讀背面之注意事項再填寫本頁) LDL代謝促進劑之實例包含:JPA Η7(1995)-316144所 述,Μ下式表示之化合物或其塩,
(式中,R4, R5, R6及R7為相同或不同,示氫原子,鹵原 子,低級烧基或低級燒氧基;r為0〜2; s為2〜4; p為1〜 2);特別是N-[2-[4-雙(4-氟苯基)甲基-1-六氫吡阱基]乙 基卜7,7-二苯基-2,4,6-庚三烯酸醯胺,等。 上述鯊烯合成抑制劑,費布雷化合物及L D L代謝促進 v.r 劑,可Μ其他具有降低血中膽固醇及三酸甘油酯量之性質 之藥物取代之。此等藥物之實例,包含:菸驗酸衍生物, 例如,菸驗酸環己醇酯(nicomol)及菸驗酸戊四醇酯 (niceritrol);抗氧化劑,例如,丙丁酚(probucol);及 雛子交換樹脂,例如,降膽敏(colestyramin)。 經濟部智慧財產局員工消費合作社印製 依本發明提供之醫藥組成物,即包括:胰島素敏感性 促進劑與選自醛醣遷原酶抑制劑,鯊烯合成抑制劑,費布 雷化合物及L D L代謝促進劑抑制劑之群中之至少一員之混 合的翳藥組成物,可使各活性成分全部或分別與生理學上 可接受之載劑,賦形劑,黏合劑,稀釋劑,等混合,及使 混合物(等)作為翳藥組成物經口或非經口給予之。若活性 成分經分別調配,各調配劑可Μ稀釋劑等臨時混合後經一 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 21 3 8 259 1238064 A7 B7 五、發明説明(2 2 ) 次或間隔次數給予,或彼此分別給予相同病患。 (請先閱讀背面之注意事項再填寫本頁) 此醫藥組成物之劑型,包含:口服劑型,如粒劑,粉 劑,錠劑,膠囊劑,漿液劑,乳劑,懸浮劑,等,及非口 服劑型,如注射劑(如,皮下,靜脈内,肌内及腹膜内注 射劑),滴注液,外用型(如,噴鼻製劑,經皮製劑,軟齋 劑,等),及栓劑(如,直腸及陰道栓劑)。 此等劑可型依常用之翳藥製程本身已知之技術製造之 。詳細之製程,如下: 經濟部智慧財產局員工消費合作社印製 製造口服劑型時,例如,賦形劑(如,乳糖,蔗糖, 澱粉,甘露糖醇,等),崩解劑(如,碳酸鈣,羧甲基纖維 素鈣,等),黏合劑(如,α-澱粉,阿拉伯膠,羧甲基纖 維素,聚乙烯吡咯麵,羥丙基纖維素,等),及潤滑劑(如 ,滑石,硬脂酸鎂,聚乙二醇6000,等),加至活性成分, 所得組成物予Μ壓縮。需要的話,經壓縮之產物,為使之 矯味或使之腸溶或緩釋,依本身已知之技術,予Μ包覆之 。可用之包覆物料,包含例如,乙基纖維素,羥甲基纖維 素,聚氧乙二醇,纖維素乙酸酞酸酯,羥丙基甲基纖維素 酞酸酯,及優雷季(Endragit)[西德,羅門哈斯(Rohm & Haas),甲基丙烯酸-丙烯酸共聚物]。 注射劑可依下述製程典型製造之。使活性成分(等)連 同分散劑[如,Tween 80(美國阿特拉斯粉末公司(Atlas Powder)], HCO 60(Nikko化學公司),聚乙二醇,羧甲基 纖維素,藻酸納,等],保存劑(如,對-羥基苯甲酸甲酿, 對-羥基苯甲酸丙酯,苯甲醇,氯丁醇,酚,等),等張劑 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 22 3 825 9 1238064 經濟部智慧財產局員工消費合作社印製 A7 B7五、發明説明(23 ) (如,氯化鈉,甘油,山梨糖醇,葡萄糖,轉化糖,等)及 其他添加物,一起溶解,懸浮或乳化於水性媒液[如,蒸 餾水,生理塩液,林格氏(R i n g e r ’ s )溶液,等]或油性媒 液(如,植物油,例如,橄攬油,芝麻油,棉籽油,玉米 油,等,或丙二醇]中。需要的話,亦可加入增溶劑(如, 水楊酸鈉,乙酸鈉,等),安定劑(如,人類血清白蛋白), 安慰劑[如,氯化苯烧鞍(benzalkonium chloride),普魯 卡因(procaine)塩酸塩,等]及其他添加物。 外用劑型,可使活性成分(等)經加工成固體,半固體 或液體組成物而製造之。製造固體組成物時,例如,將活 性成分(等)之本身,或其與賦形劑(如,乳糖,甘露糖醇, 澱粉,微晶纖維素,蔗糖,等),增稠劑(如,天然膠,纖 維素衍生物,丙烯酸聚合物,等)等之混合物,處理成粉 劑。液體組成物,可依上述注射劑之實質相同方式,製造 之。半固體組成物,宜成水性或油性凝膠型或軟裔型。此 等組成物中可任意含有pH調控劑(如,碳酸,磷酸,檸檬 酸,塩酸,氫氧化鈉,等),及保存劑(如,對-羥基苯甲 酸酯,氯丁醇,氯化苯甲烷銨,等)及其他添加劑。 栓劑,無論是固體,半固體或液體,可使活性成分( 等)加工成油性或水性組成物而製造之。可使用之油脂性 基質,包含例如,高級脂肪酸甘油酯[如,可可脂, Witepsols(Dinamit-Nobel),等],中级一鏈脂肪酸[如, Migriols(Dinamit-Nobel),等],植物油(如,芝麻油, 大豆油,棉籽油,等),等。水溶性基質,包含例如,聚 (請先閲讀背面之注意事項再填寫本頁)
•II 1T----- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 23 3 8 2 59 1238064 A7 B7 五、發明説明(24 經濟部智慧財產局員工消費合作社印製 , 丨。之重成胰至 go 合別每 受型之 較予 ,力物 膠 類卜分體性之οι/ko.混各乃 接劑擇 比給較耐成 然。乳猴成及活人0.rag宜。考宜 依,選 分別比糖組 天等哺,性舲及成圍Μ5β(之參較 可間宜 成各鼠萄藥 ,,用豬活年,,範 5 擇可, ,時合 性分大葡發 如物全,別者法如量 050 選亦數 例藥, 活成胖低之 例合安馬各受方例劑so/k,,次 比給子 種性Γ)降明 含聚可,考接藥。服fflgi)#)藥 之,因 一活ta及發 包酸且牛參,給之口10體("給 分況他 任等is症本 ,烯,,可者,擇床,至 g 分。 成狀其 予此(W糖 , 質丙微貓 ,受型選臨iia05/k成之 性床及 給與達血是 基及低 ,量接劑宜於 g.omg性用 活臨合 只,士高於 性,性狗劑依,合可/ksoll活使 ,時混 與如威對。 水物毒 ,之 可間而 ,g l 他擇 中當之 ,例性 ,果 親合物兔物且時 ,量!0_.0其選 物 ,分 物。病予效 鼉 9 。 聚成 ,成 ,藥子劑至 jio之, 成重成 成果尿給良 5 0^ 宜 等烯組鼠組定給因之051IH 型圍 組體性 組效糖合改 ,乙藥大藥決 ,他劑 OI 類範 藥及活 藥合之混之 醇 ,醫 ,醫宜況 其進宜 MB用量 翳龄及 醫協 症分顯 二物之鼠之合狀及促S(H11作劑 之年 , 之之胖成明 丙生明小明而床 ,性 — ig 同床。明者法 明顯肥性示 體臨 k ,衍發 ,發量臨合感gi/k不臨次發受方 發明性活展 醇素本人本劑時混敏/kImg之之S3本接藥 本示傳等均 二維 ,. 薦當之素fflg重10用薦 1 ,給 顯遣此 , 乙纖 如 推 ,分島10體至使推天 者 ,。 ,患則上 (請先閲讀背面之注意事項再填寫本頁) *---^訂-----Γ. 線» 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 3 8 2 5 9 1238064 A7 Β7 五、發明説明(25 ) ,在降低糖尿病之血中葡萄糖上,比只給予各成分藥物者 更有效,因此,可有效用以預防和治療糖尿病併發症。 再則,由於本發明之翳藥組成物,與只給予任一種活 性成分比較,Μ較少劑量即是達效果,因此,各別成分之 副作用(如,腸胃性失調,如痢疾,等)可降低。 下述實施例及試驗例,僅用Μ詳述本發明,但絕不Μ 此限制本發明之範圍。 本發明之翳藥組成物,可依下述配方製備之。 實 _例1 膠 囊劑 (1)皮 利 Μ 塩 酸塩 10 (2)義 巴 達 50 (3)乳 糖 55 (4)微 晶 纖 維 素 55 (5)硬 脂 酸 鎂 10 總 量 180 mg 全量之(1), (2), (3)及(4),及1/2量之(5),經混合 均勻,依一般方式造粒。然後,加餘量之(5 ),全部組成 物裝入明膠膠囊殻。成人劑量為3膠囊劑/天,分成1至3次 給予。 本發明之醫藥組成物,對糖尿病性高血糖症,顯示強 力之制約作用,而用Μ預防及治療糖尿病。再則,此翳藥 組成物亦用以預防及治療糖尿病併發症,例如,糖尿病性 i_= = n - -:- -!-l —11 -- ί-. 1— 經濟部智慧財產局員工消費合作社印製 • -----------訂 -----hls------h---1JI— (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 2 5 3 8 2 5 9 ί>| A7 1238064 B7 五、發明説明(26) 神經病,腎病,視網膜病,巨血管病(macroangiopathy), 及骨質減少症(〇 s t e 〇 p e n i a )。此外,依臨床狀況,合宜選 擇成分藥物之種類,給藥途徑,劑量,等,可Μ極低副作 用機率,達成長期治療之安定低血糖效果。 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 26 3 82 5 9
Claims (1)
- !238〇64 Η3 第90105054號專利申請案 申請專利範圍修正本 (94年4月26日) 一種預防及治療糖尿病用之醫藥組成物,包括:(Α)胰島素敏感性促 進劑與(Β)費布雷(f ibrate)化合物或利米萊(glimepiride);其中(Α) 對(B)之重量比爲1:0.0001至5;其中胰島素敏感性促進劑爲皮利酮 (pioglitazone)、5-[[4-[2-(甲基-2·吡啶基胺基)乙氧基]苯基]-甲 基]-2,4-噻唑啶二酮、或其等之藥理學上可接受之塩; 及 費布雷化合物爲朋費布雷(bezafibrate),貝可布雷 (beclobrate),畢尼費布雷(binifibrate),賽普費布雷 (ciplofibrate),克諾費布雷(clinofibrate),袪脂乙酯 (clofibrate),法脂酸(clofibric acid),艾費布雷(etofibrate), 芬費布雷(fenofibrate),金費伯兹(gemfibrozil),尼可費布雷 (nicofibrate),派利費布雷(pirifibrate),羅尼費布雷 (ronifibrate),辛費布雷(simfibrate)或席費布雷(theofibrate)。 經濟部中央榡準局員工福利委員會印製 •如申請專利範圍第1項之醫藥組成物,其中,胰島素敏感性促進劑 爲皮利酮(pioglit azone)或其塩。 •如申請專利範圍第1項之醫藥組成物,其中,胰島素敏感性促進劑爲 5-[ [4-[2-(甲基-2-吡啶基胺基)乙氧基]苯基卜甲基]-2,4-噻唑啶二 酮或其塩。 •如申請專利範圍第1項之醫藥組成物,其係包含皮利酮或其塩及利米 萊 本紙張尺度適用中國國家標準(CMS) Α4規格(210 X 297公釐) 27 38259D1修正本
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15350095 | 1995-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI238064B true TWI238064B (en) | 2005-08-21 |
Family
ID=15563926
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW090105054A TWI238064B (en) | 1995-06-20 | 1996-06-12 | A pharmaceutical composition for prophylaxis and treatment of diabetes |
TW085107042A TW438587B (en) | 1995-06-20 | 1996-06-12 | A pharmaceutical composition for prophylaxis and treatment of diabetes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW085107042A TW438587B (en) | 1995-06-20 | 1996-06-12 | A pharmaceutical composition for prophylaxis and treatment of diabetes |
Country Status (26)
Country | Link |
---|---|
US (44) | US5952356A (zh) |
EP (6) | EP0749751A3 (zh) |
JP (3) | JP3148973B2 (zh) |
KR (3) | KR970000233A (zh) |
CN (3) | CN1289082C (zh) |
AR (4) | AR005641A1 (zh) |
AT (2) | ATE256463T1 (zh) |
CA (3) | CA2531834C (zh) |
CY (4) | CY2424B1 (zh) |
CZ (2) | CZ291624B6 (zh) |
DE (4) | DE122009000064I1 (zh) |
DK (2) | DK1174135T3 (zh) |
ES (2) | ES2327383T5 (zh) |
FR (1) | FR09C0055I2 (zh) |
HK (2) | HK1010484A1 (zh) |
HU (1) | HUP9601698A3 (zh) |
LU (2) | LU91298I2 (zh) |
MX (1) | MX9602399A (zh) |
MY (1) | MY127530A (zh) |
NL (2) | NL300258I2 (zh) |
NO (5) | NO313226B1 (zh) |
PT (2) | PT861666E (zh) |
RU (5) | RU2198682C2 (zh) |
SK (2) | SK287287B6 (zh) |
TW (2) | TWI238064B (zh) |
ZA (1) | ZA965190B (zh) |
Families Citing this family (254)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
CA2180296C (en) * | 1995-07-03 | 2007-01-09 | Yoshio Tsujita | Treatment of arteriosclerosis and xanthoma |
CN1192683A (zh) | 1995-08-10 | 1998-09-09 | 沃尼尔·朗伯公司 | 减少非胰岛素依赖型糖尿病患者外源性胰岛素给药量的方法 |
NZ330774A (en) | 1996-04-05 | 1999-06-29 | Takeda Chemical Industries Ltd | Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity |
DE69731840T2 (de) | 1996-07-15 | 2005-08-04 | Sankyo Co., Ltd. | Pharmazeutische Zusammensetzungen enthaltend CS-866 und Insulinresistenz verbessernde Mittel und deren Verwendung zur Behandlung von Arteriosklerose und Xanthom |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US6291495B1 (en) | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
AU778947B2 (en) * | 1997-06-18 | 2004-12-23 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and metformin |
AU783539B2 (en) * | 1997-06-18 | 2005-11-10 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and sulphonylurea |
AU8799998A (en) * | 1997-06-18 | 1999-01-04 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor |
AU8539298A (en) * | 1997-06-18 | 1999-01-04 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and sulphonylurea |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
US20020028768A1 (en) * | 1997-06-18 | 2002-03-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with rosiglitazone and insulin |
AP1279A (en) * | 1997-06-18 | 2004-05-20 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and metformin. |
US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
GB9715306D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
GB9715298D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
US20020016287A1 (en) * | 1997-07-18 | 2002-02-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
GB9715295D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
AU782419B2 (en) * | 1997-07-18 | 2005-07-28 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
TR200001056T2 (tr) * | 1997-10-20 | 2000-09-21 | Dainippon Pharmaceutical Co., Ltd. | Hızlı çözülen farmasötik terkipler. |
US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
ES2317688T3 (es) | 1998-01-29 | 2009-04-16 | Amgen Inc. | Moduladores ppar-gamma. |
US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
US7105552B2 (en) * | 1998-05-08 | 2006-09-12 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
ES2255316T3 (es) * | 1998-06-30 | 2006-06-16 | Takeda Pharmaceutical Company Limited | Composicion farmaceutica para el tratamiento de diabetes. |
JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
EP0974356B1 (en) | 1998-07-15 | 2003-09-24 | Merck Sante | Tablets comprising a combination of metformin and glibenclamide |
US6376549B1 (en) * | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
CN1328456A (zh) * | 1998-10-29 | 2001-12-26 | 德克萨斯大学董事会 | 噻唑烷二酮衍生物用于防止早产或哺乳时子宫收缩的用途 |
DZ2937A1 (fr) * | 1998-11-12 | 2004-03-15 | Smithkline Beecham Plc | Compositions nouvelles de sensibilidants à l'insuline. |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
DE69939485D1 (de) * | 1998-11-12 | 2008-10-16 | Smithkline Beecham Plc | Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
AP1692A (en) * | 1998-11-12 | 2006-12-12 | Smithkline Beecham Plc | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent. |
US6958324B2 (en) | 1998-12-02 | 2005-10-25 | Inotek Pharmaceuticals Corporation | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
US6756360B1 (en) | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
PT1143955E (pt) * | 1998-12-24 | 2005-11-30 | Metabasis Therapeutics Inc | Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete |
DE60039410D1 (de) * | 1999-01-29 | 2008-08-21 | Takeda Pharmaceutical | Verdichtungshammer mit beschichtungsbehandlung |
JP4799720B2 (ja) * | 1999-01-29 | 2011-10-26 | 武田薬品工業株式会社 | コーティング処理を施した打錠用杵 |
GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
CN101165036A (zh) * | 1999-04-01 | 2008-04-23 | 埃斯佩里安医疗公司 | 醚化合物,及其组合物和用途 |
US7407978B2 (en) * | 1999-04-06 | 2008-08-05 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
JP2000355550A (ja) * | 1999-04-14 | 2000-12-26 | Takeda Chem Ind Ltd | ケトーシス改善剤 |
TWI249401B (en) * | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
DE60037602T2 (de) * | 1999-04-23 | 2009-01-08 | Smithkline Beecham P.L.C., Brentford | Herstellung einer polymorphen Form eines Thiazolidindionderivates |
GB9910693D0 (en) * | 1999-05-07 | 1999-07-07 | Univ Liverpool | A compound for use in medicine |
US6214842B1 (en) * | 1999-05-12 | 2001-04-10 | Michael S. Malamas | Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia |
AU770870B2 (en) * | 1999-06-18 | 2004-03-04 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
PT1133312E (pt) | 1999-06-21 | 2007-11-30 | Lilly Co Eli | Uso sinergístico de tiazolidinodionas com péptido 1 semelhante ao glucagon e os seus agonistas para tratar diabetes não insulino-dependente |
CA2369839A1 (en) * | 1999-06-25 | 2001-01-04 | Minimed, Inc. | Compositions of insulin and insulin-related peptide for treating diabetes |
AU779730B2 (en) * | 1999-06-30 | 2005-02-10 | Amgen, Inc. | Compounds for the modulation of PPARgamma activity |
JP4295458B2 (ja) * | 1999-06-30 | 2009-07-15 | アムジェン インコーポレイテッド | Ppar−ガンマ活性調節用化合物 |
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
US6878749B2 (en) | 1999-09-17 | 2005-04-12 | Novartis Ag | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
CO5200844A1 (es) * | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
AU2005200818B2 (en) * | 1999-09-17 | 2008-07-17 | Novartis Ag | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
AU780855B2 (en) * | 1999-10-06 | 2005-04-21 | Kurokawa, Kiyoshi | Carbonyl stress-decreasing agent |
EP1218015A2 (en) * | 1999-10-08 | 2002-07-03 | Novartis AG | Pharmaceutical composition of nateglinide and another antidiabetic agent |
US6274622B1 (en) * | 1999-10-27 | 2001-08-14 | Frederick H. Hausheer | Method of treating diabetic ophthalmopathy |
CN1450902A (zh) | 1999-11-03 | 2003-10-22 | 布里斯托尔-迈尔斯斯奎布公司 | 包含二甲双胍和格列本脲组合的药用组合物 |
US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
AR030920A1 (es) * | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
US6660021B1 (en) | 1999-12-23 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Intravascular device and system |
US6402771B1 (en) | 1999-12-23 | 2002-06-11 | Guidant Endovascular Solutions | Snare |
US6575997B1 (en) | 1999-12-23 | 2003-06-10 | Endovascular Technologies, Inc. | Embolic basket |
GB9930688D0 (en) * | 1999-12-24 | 2000-02-16 | Smithkline Beecham Plc | Novel method of treatment |
JP2003518493A (ja) * | 1999-12-24 | 2003-06-10 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 新規治療方法 |
US6695813B1 (en) | 1999-12-30 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Embolic protection devices |
US7918820B2 (en) | 1999-12-30 | 2011-04-05 | Advanced Cardiovascular Systems, Inc. | Device for, and method of, blocking emboli in vessels such as blood arteries |
US20010036479A1 (en) | 2000-01-14 | 2001-11-01 | Gillian Cave | Glyburide composition |
AU2001229601A1 (en) * | 2000-01-24 | 2001-07-31 | Inotek Corporation | Method and composition for modulating an immune response |
US6540982B1 (en) * | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
EP1254667A4 (en) * | 2000-02-10 | 2003-03-12 | Takeda Chemical Industries Ltd | MEDICINE COMPRISING A COMBINATION |
EP1295609A4 (en) * | 2000-02-24 | 2004-11-03 | Takeda Chemical Industries Ltd | DRUGS CONTAINING COMBINED ACTIVE INGREDIENTS |
US6548049B1 (en) * | 2000-05-01 | 2003-04-15 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
US6461639B2 (en) * | 2000-05-01 | 2002-10-08 | Aeropharm Technology, Inc. | Core formulation |
US6610272B1 (en) * | 2000-05-01 | 2003-08-26 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US6451342B2 (en) * | 2000-05-01 | 2002-09-17 | Aeropharm Technology Incorporated | Core formulation comprised of troglitazone and a biguanide |
US6296874B1 (en) * | 2000-05-01 | 2001-10-02 | Aeropharm Technology Incorporated | Core formulation comprising troglitazone and abiguanide |
WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
US6270797B1 (en) * | 2000-05-18 | 2001-08-07 | Usv Limited | Sustained release pharmaceutical composition containing glipizide and method for producing same |
US6939362B2 (en) * | 2001-11-27 | 2005-09-06 | Advanced Cardiovascular Systems, Inc. | Offset proximal cage for embolic filtering devices |
US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
US7563774B2 (en) | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
US6964670B1 (en) | 2000-07-13 | 2005-11-15 | Advanced Cardiovascular Systems, Inc. | Embolic protection guide wire |
PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
US20060089389A1 (en) * | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US20080241070A1 (en) * | 2000-09-21 | 2008-10-02 | Elan Pharma International Ltd. | Fenofibrate dosage forms |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
MXPA03003204A (es) * | 2000-10-12 | 2004-12-03 | Nissan Chemical Ind Ltd | Agente terapeutico y profilactico para complicaciones diabeticas. |
US6506203B1 (en) | 2000-12-19 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Low profile sheathless embolic protection system |
CA2434169C (en) | 2001-01-12 | 2011-03-15 | Sun Pharmaceutical Industries Limited | Spaced drug delivery system |
WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
DE60204611T2 (de) | 2001-02-28 | 2006-05-11 | Pfizer Products Inc., Groton | Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren |
MXPA03007451A (es) * | 2001-03-02 | 2004-10-15 | Lichtwer Pharma Ag | Medicamento para tratar la diabetes mellitus. |
KR200249057Y1 (ko) * | 2001-03-22 | 2001-10-19 | 김진환 | 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치 |
ES2231681T3 (es) | 2001-03-30 | 2005-05-16 | Pfizer Products Inc. | Inhibidores de piridazinona de la aldosa reductasa. |
WO2002080924A1 (fr) * | 2001-04-03 | 2002-10-17 | Yamanouchi Pharmaceutical Co., Ltd. | Nouvelle utilisation du derive sulfonamide arylethene |
CA2443632C (en) * | 2001-04-10 | 2011-05-03 | Sun Pharmaceutical Industries Limited | Timed pulse release composition |
SE0101982D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
JP2002360666A (ja) * | 2001-06-11 | 2002-12-17 | Takeda Chem Ind Ltd | コバルト合金を用いた打錠用杵臼 |
US6737401B2 (en) * | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
US7338510B2 (en) | 2001-06-29 | 2008-03-04 | Advanced Cardiovascular Systems, Inc. | Variable thickness embolic filtering devices and method of manufacturing the same |
US6599307B1 (en) | 2001-06-29 | 2003-07-29 | Advanced Cardiovascular Systems, Inc. | Filter device for embolic protection systems |
MXPA04000176A (es) * | 2001-07-10 | 2004-10-27 | Kos Life Sciences Inc | Formulacion de nucleo. |
AU2001273289B2 (en) * | 2001-07-10 | 2004-10-07 | Kos Life Sciences, Inc. | Core formulation comprising pioglitazone hydrochloride and a biguanide |
US6638294B1 (en) | 2001-08-30 | 2003-10-28 | Advanced Cardiovascular Systems, Inc. | Self furling umbrella frame for carotid filter |
US6592606B2 (en) | 2001-08-31 | 2003-07-15 | Advanced Cardiovascular Systems, Inc. | Hinged short cage for an embolic protection device |
US8262689B2 (en) | 2001-09-28 | 2012-09-11 | Advanced Cardiovascular Systems, Inc. | Embolic filtering devices |
EP1452530A4 (en) | 2001-12-03 | 2005-11-30 | Japan Tobacco Inc | AZOL CONNECTION AND THEIR MEDICAL USE |
US7241304B2 (en) | 2001-12-21 | 2007-07-10 | Advanced Cardiovascular Systems, Inc. | Flexible and conformable embolic filtering devices |
DE10200138A1 (de) * | 2002-01-04 | 2003-07-17 | Karl Winkler | Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors |
TWI327462B (en) * | 2002-01-18 | 2010-07-21 | Sumitomo Chemical Co | Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
TW200810743A (en) * | 2002-03-22 | 2008-03-01 | Novartis Ag | Combination of organic compounds |
US20050142065A1 (en) * | 2002-04-26 | 2005-06-30 | Koki Kato | Screening method |
US20070264348A1 (en) * | 2002-05-24 | 2007-11-15 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
PL376577A1 (pl) | 2002-06-17 | 2006-01-09 | Themis Laboratories Private Limited | Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania |
EP1549296A4 (en) | 2002-08-02 | 2006-08-09 | Penwest Pharmaceuticals Co | METFORMIN FORMULATIONS WITH DELAYED RELEASE |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
JP4694841B2 (ja) | 2002-09-20 | 2011-06-08 | アンドルックス ラボズ リミテッド ライアビリティ カンパニー | ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤 |
US9060941B2 (en) * | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7959946B2 (en) * | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7331973B2 (en) | 2002-09-30 | 2008-02-19 | Avdanced Cardiovascular Systems, Inc. | Guide wire with embolic filtering attachment |
US7252675B2 (en) | 2002-09-30 | 2007-08-07 | Advanced Cardiovascular, Inc. | Embolic filtering devices |
UA80991C2 (en) * | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
US20040088000A1 (en) | 2002-10-31 | 2004-05-06 | Muller Paul F. | Single-wire expandable cages for embolic filtering devices |
DE10252666A1 (de) * | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
IN192749B (zh) * | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
DE10261067A1 (de) * | 2002-12-24 | 2004-08-05 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure |
US8293751B2 (en) | 2003-01-14 | 2012-10-23 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
US6794401B2 (en) * | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
US7179941B2 (en) | 2003-01-23 | 2007-02-20 | Sanofi-Aventis Deutschland Gmbh | Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use |
DE10302452B4 (de) * | 2003-01-23 | 2005-02-24 | Aventis Pharma Deutschland Gmbh | Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
AU2004208606B2 (en) | 2003-01-29 | 2009-09-24 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
US7572910B2 (en) * | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
US8591540B2 (en) | 2003-02-27 | 2013-11-26 | Abbott Cardiovascular Systems Inc. | Embolic filtering devices |
WO2004108067A2 (en) * | 2003-04-03 | 2004-12-16 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
CA2521830A1 (en) * | 2003-04-09 | 2004-10-21 | Japan Tobacco Inc. | Heteroaromatic pentacyclic compound and medicinal use thereof |
US7820158B2 (en) * | 2003-04-10 | 2010-10-26 | Surmodics, Inc. | Ligand-coupled initiator polymers and methods of use |
WO2004096276A1 (ja) * | 2003-04-28 | 2004-11-11 | Sankyo Company, Limited | 糖取り込み能増強剤 |
EP1621210B1 (en) * | 2003-04-28 | 2013-06-19 | Daiichi Sankyo Company, Limited | Adiponectin production enhancer |
US7230016B2 (en) * | 2003-05-13 | 2007-06-12 | Synthon Ip Inc. | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
US20050059708A1 (en) * | 2003-05-13 | 2005-03-17 | Karel Pospisilik | Processes for making thiazolidinedione derivatives and compounds thereof |
US20050004179A1 (en) * | 2003-05-22 | 2005-01-06 | Pedersen Ward A. | Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease |
JP2007506649A (ja) * | 2003-06-27 | 2007-03-22 | ドクター レディーズ リサーチ ファンデーション | バラグリタゾンとさらなる抗糖尿病化合物とを含む組成物 |
US20050013863A1 (en) * | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
CA2534432A1 (en) * | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
EP1510208A1 (en) * | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
WO2005039626A2 (en) * | 2003-10-27 | 2005-05-06 | Innodia Inc. | Use of hydroxylated amino acids for treating diabetes |
RU2359661C2 (ru) | 2003-10-31 | 2009-06-27 | Такеда Фармасьютикал Компани Лимитед | Твердый препарат |
US7892251B1 (en) | 2003-11-12 | 2011-02-22 | Advanced Cardiovascular Systems, Inc. | Component for delivering and locking a medical device to a guide wire |
US20050163837A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Rosiglitazone formulations |
EP1841414A1 (en) * | 2003-12-31 | 2007-10-10 | Alpharma, Inc. | Rosiglitazone and metformin formulations |
US7360069B2 (en) * | 2004-01-13 | 2008-04-15 | Hewlett-Packard Development Company, L.P. | Systems and methods for executing across at least one memory barrier employing speculative fills |
JP2005200419A (ja) * | 2004-01-16 | 2005-07-28 | National Health Research Inst | 癌治療法 |
EP1714648A4 (en) * | 2004-02-09 | 2010-05-26 | Aska Pharm Co Ltd | COMBINATION DRUGS |
EP1716144A2 (en) * | 2004-02-20 | 2006-11-02 | Synthon B.V. | Processes for making pioglitazone and compounds of the processes |
WO2005084666A1 (en) * | 2004-03-02 | 2005-09-15 | Abeille Pharmaceuticals, Inc. | Co-formulations of kits of bioactive agents |
US7678129B1 (en) | 2004-03-19 | 2010-03-16 | Advanced Cardiovascular Systems, Inc. | Locking component for an embolic filter assembly |
US7161756B2 (en) * | 2004-05-10 | 2007-01-09 | Tandberg Data Storage Asa | Method and system for communication between a tape drive and an external device |
CN1327840C (zh) * | 2004-06-08 | 2007-07-25 | 天津药物研究院 | 一种药物组合物及其在制备用于治疗糖尿病中的应用 |
US20100048454A1 (en) * | 2004-08-03 | 2010-02-25 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
WO2006032011A2 (en) * | 2004-09-14 | 2006-03-23 | Elixir Pharmaceuticals, Inc. | Combination therapy for controlled carbohydrate digestion |
MXPA04009236A (es) * | 2004-09-23 | 2006-03-27 | Jorge Luis Rosado Loria | Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. |
JP2008019169A (ja) * | 2004-10-25 | 2008-01-31 | Osaka Univ | 新規ppar調節剤およびそのスクリーニング方法 |
US20060089387A1 (en) * | 2004-10-26 | 2006-04-27 | Le Huang | Stabilized pharmaceutical composition comprising antidiabetic agent |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
US9259305B2 (en) | 2005-03-31 | 2016-02-16 | Abbott Cardiovascular Systems Inc. | Guide wire locking mechanism for rapid exchange and other catheter systems |
US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
JP2009500401A (ja) * | 2005-07-07 | 2009-01-08 | ポステック ファンデーション | 糖吸収調節剤及び薬学的組成物 |
WO2007011524A1 (en) * | 2005-07-14 | 2007-01-25 | Franco Folli | Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome |
RU2376994C2 (ru) * | 2005-07-22 | 2009-12-27 | Дзе Проктер Энд Гэмбл Компани | Составы для снижения риска возникновения вызванной лекарственными средствами аритмии |
MXPA05013220A (es) * | 2005-12-06 | 2007-06-05 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2. |
NZ569071A (en) | 2005-12-22 | 2011-01-28 | Takeda Pharmaceutical | Solid preparation containing an insulin sensitizer |
FR2896157B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
WO2007105730A1 (ja) * | 2006-03-13 | 2007-09-20 | Kyowa Hakko Kogyo Co., Ltd. | インスリン抵抗性改善剤 |
AU2007227581B2 (en) | 2006-03-16 | 2012-11-08 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease |
US8338480B2 (en) * | 2006-03-31 | 2012-12-25 | Wellstat Therapeutics Corporation | Combination treatment of metabolic disorders |
EA016715B1 (ru) * | 2006-04-11 | 2012-07-30 | Сорбуотер Текнолоджи Ас | Способ удаления веществ из потока жидкости |
US7435741B2 (en) * | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
ES2376396T3 (es) | 2006-06-26 | 2012-03-13 | Amgen Inc. | Método para tratar aterosclerosis. |
US7752724B2 (en) * | 2006-06-27 | 2010-07-13 | Lumino, Inc. | Method of cutting blinds |
TW200816995A (en) * | 2006-08-31 | 2008-04-16 | Daiichi Sankyo Co Ltd | Pharmaceutical composition containing insulin sensitizers |
US20080182880A1 (en) * | 2006-09-28 | 2008-07-31 | Mailatur Sivaraman Mohan | Pioglitazone composition |
US8217025B2 (en) * | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
US20080176905A1 (en) * | 2007-01-22 | 2008-07-24 | Santiago Ini | Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof |
WO2008089521A1 (en) | 2007-01-25 | 2008-07-31 | Verva Pharmaceuticals Ltd | Insulin sensitisers and methods of treatment |
MX2009008100A (es) * | 2007-02-01 | 2009-08-07 | Takeda Pharmaceutical | Preparacion solida que comprende alogliptina y pioglitazona. |
US20080249156A1 (en) * | 2007-04-09 | 2008-10-09 | Palepu Nageswara R | Combinations of statins and anti-obesity agent and glitazones |
CN105250285B (zh) | 2007-04-11 | 2019-09-06 | 奥默罗斯公司 | 预防和治疗成瘾的组合物和方法 |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US8216209B2 (en) | 2007-05-31 | 2012-07-10 | Abbott Cardiovascular Systems Inc. | Method and apparatus for delivering an agent to a kidney |
AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US7867273B2 (en) | 2007-06-27 | 2011-01-11 | Abbott Laboratories | Endoprostheses for peripheral arteries and other body vessels |
KR20100040937A (ko) | 2007-07-26 | 2010-04-21 | 암젠 인크 | 변형된 레시틴-콜레스테롤 아실트랜스퍼라제 효소 |
CA2699289C (en) * | 2007-09-14 | 2016-01-19 | Metabolic Solutions Development Company | Thiazolidinedione analogues for the treatment of hypertension |
JPWO2009038107A1 (ja) * | 2007-09-21 | 2011-01-06 | キッセイ薬品工業株式会社 | 2型糖尿病治療用の組合せ医薬 |
WO2009073627A1 (en) * | 2007-11-30 | 2009-06-11 | The Research Foundation Of State University Of New York | Metabolic fuel switching biomarker |
US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
WO2009120844A2 (en) * | 2008-03-26 | 2009-10-01 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
PT2324126E (pt) * | 2008-08-12 | 2014-06-02 | Zinfandel Pharmaceuticals Inc | Método de identificação de factores de risco da doença de alzheimer |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
CN106692144A (zh) | 2009-03-11 | 2017-05-24 | 奥默罗斯公司 | 预防和治疗成瘾的组合物和方法 |
US20110038848A1 (en) * | 2009-08-12 | 2011-02-17 | Melaleuca, Inc. | Dietary supplement compositions for cardiovascular health |
BR112012011237A2 (pt) | 2009-11-13 | 2019-09-24 | Univ Tokyo | agente terapêutico e profilático para diabetes |
WO2011068667A1 (en) * | 2009-12-04 | 2011-06-09 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
US20130053350A1 (en) * | 2009-12-15 | 2013-02-28 | Metabolic Solutions Development Company, Llc | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
JP5634526B2 (ja) * | 2009-12-15 | 2014-12-03 | メタボリック ソリューションズ ディベロップメント カンパニー, エルエルシー | 代謝性疾患を処置するためのppar温存チアゾリジンジオン塩 |
US20140088027A1 (en) | 2010-03-30 | 2014-03-27 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
CN102918027A (zh) * | 2010-04-06 | 2013-02-06 | 艾尼纳制药公司 | Gpr119受体调节剂和对与所述受体有关的障碍的治疗 |
RU2526153C2 (ru) * | 2010-07-15 | 2014-08-20 | Олег Ильич Эпштейн | Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция |
JP2013538807A (ja) | 2010-09-01 | 2013-10-17 | ルピン・リミテッド | メトホルミンおよびピオグリタゾンを含む医薬組成物 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
CN107362165A (zh) | 2011-01-10 | 2017-11-21 | 金帆德尔制药股份有限公司 | 用于治疗阿尔茨海默病的方法和药物产品 |
SI2665477T1 (sl) * | 2011-01-20 | 2016-02-29 | Bionevia Pharmaceuticals Inc. | Modificirano sproščanje epalrestata ali njegovega derivata in metode za uporabo le-teh |
WO2013034174A1 (en) | 2011-09-06 | 2013-03-14 | ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. | Solid preparations of pioglitazone and glimepiride |
EA201891154A1 (ru) | 2011-10-28 | 2019-02-28 | ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей |
AU2012347540A1 (en) | 2011-12-08 | 2014-06-26 | Amgen Inc. | Agonistic human LCAT antigen binding proteins and their use in therapy |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
EP3065757A4 (en) | 2013-10-09 | 2017-08-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
RU2572706C1 (ru) * | 2014-06-30 | 2016-01-20 | Олег Ильич Эпштейн | Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция |
MX2017010131A (es) | 2015-02-06 | 2017-11-01 | Intercept Pharmaceuticals Inc | Composiciones farmaceuticas para terapia combinada. |
MA42807A (fr) | 2015-06-22 | 2018-07-25 | Arena Pharm Inc | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1 |
US20190350907A1 (en) | 2017-01-16 | 2019-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing cd95- mediated cell motility |
WO2019241576A1 (en) | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for lowering blood sugar with a metformin pharmaceutical composition |
BR112021024109A2 (pt) | 2019-05-30 | 2022-03-22 | Intercept Pharmaceuticals Inc | Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática |
CN112869173A (zh) * | 2021-01-18 | 2021-06-01 | 广州富诺营养科技有限公司 | 一种复合维生素矿物质制剂及其制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3454635A (en) | 1965-07-27 | 1969-07-08 | Hoechst Ag | Benzenesulfonyl-ureas and process for their manufacture |
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5728073A (en) * | 1980-07-29 | 1982-02-15 | Takeda Chem Ind Ltd | Inhibitor for aldose reducing enzyme |
US4863922A (en) | 1984-12-12 | 1989-09-05 | Merck & Co., Inc. | Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
JPH01503460A (ja) | 1987-03-20 | 1989-11-22 | アルコン ラボラトリーズ、インコーポレイテツド | 糖尿病における、インシュリン感受性を増強させるためのアルドース還元酵素阻害剤の使用 |
DE3729209A1 (de) * | 1987-09-01 | 1989-03-09 | Boehringer Mannheim Gmbh | Verwendung von bezafibrat zur behandlung von diabetes |
ATE186724T1 (de) | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
US4895862A (en) * | 1989-04-21 | 1990-01-23 | American Home Products Corp. | Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
US5068342A (en) | 1989-10-27 | 1991-11-26 | American Home Products Corporation | 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof |
US5356913A (en) * | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
JPH0466579A (ja) * | 1990-07-04 | 1992-03-02 | Yamanouchi Pharmaceut Co Ltd | チアゾリジン誘導体 |
JPH0469383A (ja) * | 1990-07-06 | 1992-03-04 | Yamanouchi Pharmaceut Co Ltd | 置換チアゾリジン誘導体 |
US5260275A (en) * | 1990-08-14 | 1993-11-09 | Amylin Pharmaceuticals, Inc. | Hypoglycemics |
CA2052014A1 (en) * | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
JP2686861B2 (ja) * | 1991-03-30 | 1997-12-08 | キッセイ薬品工業株式会社 | 新規なベンジリデンコハク酸誘導体 |
JPH06510286A (ja) * | 1991-08-26 | 1994-11-17 | ファルマシア・アンド・アップジョン・カンパニー | 3−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物 |
JPH05202042A (ja) * | 1992-01-24 | 1993-08-10 | Sankyo Co Ltd | 糖尿病性合併症治療剤 |
JPH07316144A (ja) * | 1994-03-29 | 1995-12-05 | Sankyo Co Ltd | ジフェニルメチルピペラジン誘導体 |
TW403748B (en) * | 1994-11-02 | 2000-09-01 | Takeda Chemical Industries Ltd | An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same |
US5674900A (en) * | 1995-06-06 | 1997-10-07 | Shaman Pharmaceuticals, Inc. | Terpenoid-type quinones for treatment of diabetes |
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
CA2180296C (en) * | 1995-07-03 | 2007-01-09 | Yoshio Tsujita | Treatment of arteriosclerosis and xanthoma |
US5859037A (en) | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
GB9715298D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
US6001049A (en) * | 1998-02-12 | 1999-12-14 | Frey; Mark P. | Light weight exercise apparatus |
-
1996
- 1996-06-12 TW TW090105054A patent/TWI238064B/zh not_active IP Right Cessation
- 1996-06-12 TW TW085107042A patent/TW438587B/zh not_active IP Right Cessation
- 1996-06-18 JP JP15672596A patent/JP3148973B2/ja not_active Expired - Lifetime
- 1996-06-18 SK SK1449-2001A patent/SK287287B6/sk not_active IP Right Cessation
- 1996-06-18 SK SK794-96A patent/SK287351B6/sk not_active IP Right Cessation
- 1996-06-19 RU RU96111958/14K patent/RU2198682C2/ru active IP Right Maintenance
- 1996-06-19 RU RU2002104459/63A patent/RU2327455C2/ru active
- 1996-06-19 CZ CZ19961811A patent/CZ291624B6/cs not_active IP Right Cessation
- 1996-06-19 US US08/667,979 patent/US5952356A/en not_active Expired - Lifetime
- 1996-06-19 CN CNB021491313A patent/CN1289082C/zh not_active Expired - Fee Related
- 1996-06-19 CN CNA021491321A patent/CN1530106A/zh active Pending
- 1996-06-19 MX MX9602399A patent/MX9602399A/es active IP Right Grant
- 1996-06-19 RU RU96111958/63A patent/RU2323004C2/ru active
- 1996-06-19 CN CNB961110635A patent/CN1212117C/zh not_active Expired - Lifetime
- 1996-06-19 AR ARP960103195A patent/AR005641A1/es not_active Application Discontinuation
- 1996-06-19 RU RU2002104459/14K patent/RU2223760C2/ru active IP Right Maintenance
- 1996-06-19 NO NO19962606A patent/NO313226B1/no not_active IP Right Cessation
- 1996-06-19 ZA ZA9605190A patent/ZA965190B/xx unknown
- 1996-06-20 DE DE200912000064 patent/DE122009000064I1/de active Pending
- 1996-06-20 PT PT98200252T patent/PT861666E/pt unknown
- 1996-06-20 CA CA002531834A patent/CA2531834C/en not_active Expired - Lifetime
- 1996-06-20 DK DK01203170T patent/DK1174135T3/da active
- 1996-06-20 EP EP96304570A patent/EP0749751A3/en not_active Ceased
- 1996-06-20 AT AT98200252T patent/ATE256463T1/de active
- 1996-06-20 PT PT01203170T patent/PT1174135E/pt unknown
- 1996-06-20 DE DE69631157T patent/DE69631157T2/de not_active Expired - Lifetime
- 1996-06-20 HU HU9601698A patent/HUP9601698A3/hu not_active Application Discontinuation
- 1996-06-20 EP EP10012501A patent/EP2289556A3/en not_active Withdrawn
- 1996-06-20 EP EP98200252A patent/EP0861666B1/en not_active Revoked
- 1996-06-20 ES ES01203170.4T patent/ES2327383T5/es not_active Expired - Lifetime
- 1996-06-20 MY MYPI96002486A patent/MY127530A/en unknown
- 1996-06-20 ES ES98200252T patent/ES2212208T3/es not_active Expired - Lifetime
- 1996-06-20 EP EP01203170.4A patent/EP1174135B2/en not_active Expired - Lifetime
- 1996-06-20 DE DE69637988T patent/DE69637988D1/de not_active Expired - Lifetime
- 1996-06-20 AT AT01203170T patent/ATE438397T1/de active
- 1996-06-20 DK DK98200252T patent/DK0861666T3/da active
- 1996-06-20 KR KR1019960022615A patent/KR970000233A/ko not_active Application Discontinuation
- 1996-06-20 CA CA2533845A patent/CA2533845C/en not_active Expired - Fee Related
- 1996-06-20 CA CA002179584A patent/CA2179584C/en not_active Expired - Lifetime
- 1996-06-20 EP EP06022352A patent/EP1764110A1/en not_active Withdrawn
- 1996-06-20 EP EP10012500A patent/EP2292268A1/en not_active Withdrawn
-
1997
- 1997-12-26 JP JP36075697A patent/JP3973280B2/ja not_active Expired - Lifetime
-
1998
- 1998-04-09 US US09/057,465 patent/US5965584A/en not_active Expired - Lifetime
- 1998-10-22 HK HK98111476A patent/HK1010484A1/xx not_active IP Right Cessation
-
1999
- 1999-03-30 US US09/280,710 patent/US6150383A/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,470 patent/US6166042A/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,496 patent/US6121295A/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,493 patent/US6150384A/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,468 patent/US6169099B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,492 patent/US6166043A/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,494 patent/US6172089B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,508 patent/US6214848B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,495 patent/US6172090B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,497 patent/US6156773A/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,469 patent/US6133293A/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,098 patent/US6080765A/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,097 patent/US6225326B1/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,095 patent/US6174904B1/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,099 patent/US6133295A/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,096 patent/US6121294A/en not_active Expired - Lifetime
- 1999-08-31 US US09/386,504 patent/US6169100B1/en not_active Expired - Lifetime
- 1999-08-31 US US09/386,457 patent/US6103742A/en not_active Expired - Lifetime
- 1999-12-03 US US09/453,521 patent/US6329404B1/en not_active Expired - Lifetime
-
2000
- 2000-06-29 US US09/605,704 patent/US6303640B1/en not_active Expired - Lifetime
- 2000-06-29 US US09/606,176 patent/US6211205B1/en not_active Expired - Lifetime
- 2000-07-06 US US09/610,992 patent/US6288090B1/en not_active Expired - Lifetime
- 2000-07-06 US US09/610,993 patent/US6232330B1/en not_active Expired - Lifetime
- 2000-07-06 US US09/610,994 patent/US6218409B1/en not_active Expired - Lifetime
- 2000-07-18 US US09/618,635 patent/US6251924B1/en not_active Expired - Lifetime
- 2000-07-18 US US09/618,634 patent/US6323225B1/en not_active Expired - Lifetime
- 2000-07-18 US US09/618,636 patent/US6239153B1/en not_active Expired - Lifetime
- 2000-07-19 US US09/619,641 patent/US6211207B1/en not_active Expired - Lifetime
- 2000-07-19 US US09/619,640 patent/US6211206B1/en not_active Expired - Lifetime
- 2000-09-01 NO NO20004345A patent/NO314065B1/no not_active IP Right Cessation
- 2000-11-28 US US09/722,291 patent/US6277869B1/en not_active Expired - Lifetime
- 2000-11-28 US US09/722,597 patent/US6271243B1/en not_active Expired - Lifetime
- 2000-11-28 US US09/722,330 patent/US6274605B1/en not_active Expired - Lifetime
-
2001
- 2001-07-19 US US09/907,768 patent/US20020002186A1/en not_active Abandoned
- 2001-10-11 US US09/973,689 patent/US6384062B1/en not_active Expired - Lifetime
-
2002
- 2002-02-21 HK HK02101272.5A patent/HK1041203B/zh not_active IP Right Cessation
- 2002-02-28 US US10/084,479 patent/US20020123512A1/en not_active Abandoned
- 2002-03-08 NO NONO/SPC/2A patent/NO317341B1/no not_active IP Right Cessation
- 2002-03-13 US US10/095,453 patent/US6599923B2/en not_active Expired - Lifetime
- 2002-07-15 CZ CZ20022453A patent/CZ292093B6/cs not_active IP Right Cessation
-
2003
- 2003-06-17 US US10/462,793 patent/US6911459B2/en not_active Expired - Fee Related
- 2003-10-20 RU RU2003130978/14A patent/RU2286148C2/ru not_active IP Right Cessation
-
2004
- 2004-02-19 CY CY0400010A patent/CY2424B1/xx unknown
- 2004-07-26 US US10/898,316 patent/US20040266830A1/en not_active Abandoned
- 2004-09-10 US US10/937,494 patent/US7144900B2/en not_active Expired - Fee Related
- 2004-10-07 KR KR1020040079966A patent/KR20070081135A/ko not_active Application Discontinuation
-
2006
- 2006-09-20 US US11/523,771 patent/US7538125B2/en not_active Expired - Fee Related
- 2006-12-20 LU LU91298C patent/LU91298I2/fr unknown
-
2007
- 2007-01-04 NO NO2007001C patent/NO2007001I2/no unknown
- 2007-01-08 DE DE200712000002 patent/DE122007000002I1/de active Granted
- 2007-01-08 CY CY200700001C patent/CY2007001I1/el unknown
- 2007-01-25 NL NL300258C patent/NL300258I2/nl unknown
- 2007-04-25 JP JP2007115861A patent/JP4809806B2/ja not_active Expired - Lifetime
- 2007-05-28 AR ARP070102280A patent/AR061195A2/es not_active Application Discontinuation
- 2007-06-04 NO NO2007007C patent/NO2007007I2/no unknown
- 2007-12-20 KR KR1020070134272A patent/KR20080005162A/ko not_active Application Discontinuation
-
2008
- 2008-02-20 AR ARP080100677A patent/AR065389A2/es not_active Application Discontinuation
-
2009
- 2009-03-20 US US12/382,691 patent/US7842706B2/en not_active Expired - Fee Related
- 2009-09-09 LU LU91606C patent/LU91606I2/fr unknown
- 2009-10-20 CY CY0900011A patent/CY2608B2/xx unknown
- 2009-10-23 FR FR09C0055C patent/FR09C0055I2/fr active Active
- 2009-12-01 CY CY2009018C patent/CY2009018I2/el unknown
-
2010
- 2010-01-15 NL NL300432C patent/NL300432I2/en unknown
- 2010-10-19 US US12/923,975 patent/US20110034518A1/en not_active Abandoned
-
2011
- 2011-01-06 AR ARP110100033 patent/AR091289A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI238064B (en) | A pharmaceutical composition for prophylaxis and treatment of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |